SPartners Incubator, a partnership between Servier and BioLabs, provides fully equipped lab space, modular workspaces, and a collaborative ecosystem at Servier's Paris-Saclay R&D center to empower biotech startups addressing unmet medical needs. It exists to accelerate early-stage biotech ventures by combining BioLabs' operational excellence with Servier's scientific expertise, offering a competitive price point and a Golden Ticket incentive for startups aligned with Servier's priority areas.

- Startup must be a biotech company addressing an unmet medical need. - Priority given to startups developing solutions in Servier's priority areas (e.g., oncology, immunology, rare diseases). - Preference for early-stage ventures (pre-seed/seed) that can benefit from lab access and mentorship. - Scientific feasibility and innovation of the proposed technology. - Team's expertise and ability to execute the project. - Potential for collaboration with Servier's R&D and integration into the Paris-Saclay ecosystem. - Application completeness and submission before December 1st for Golden Ticket consideration.

The page does not list specific past winners, but typical SPartners cohorts include early-stage biotech startups focused on drug discovery, diagnostics, and therapeutic platforms. Archetypes include companies developing novel small molecules, biologics, or AI-driven drug development tools, often with a strong scientific founder and a clear unmet medical need.

A pre-seed/seed biotech startup with a validated proof-of-concept addressing a clear unmet medical need, ideally in Servier's priority areas (oncology, immunology, rare diseases). The founder should have a strong scientific background, a clear roadmap for lab-based validation, and a willingness to collaborate with Servier's scientists in the Paris-Saclay ecosystem.